Tuesday, March 28, 2023
Clinical Advances in
Read Overview
Supported by an independent educational grant from BeiGene
Rapid Fire
BTKi for Waldenström macroglobulinemia
Rapid Fire
BTKi for Chronic Lymphocytic Leukemia
New Challenge
New Challenge
Steering Committee Chair
Medical Director
Comprehensive Cancer Center Ulm
Institute of Experimental Cancer Research
University Hospital Ulm
Ulm, Germany
Clinical Lead
UCLH Centre for Waldenström’s Macroglobulinemia
Consultant Hematologist and Associate Professor
Department of Hematology at UCL NHS Foundation Trust
London, United Kingdom
Associate Professor
Consultant Hematologist
Department for Internal Medicine
Secretary of the GLLSG
University Hospital of Cologne
Cologne, Germany
Head of Lymphoma Service,
Alfred Hospital
Professor of Haematology,
Monash University
Melbourne, Australia
Medical Director
Hematology Department
Niguarda Cancer Center
Milan, Italy
Professor
Harvard Medical School Director
Bing Center for Waldenström's Macroglobulinemia
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Clinical Research Director
Division of Lymphoma
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA
Steering Committee Chair
Has disclosed no relevant financial relationships.
Steering Committee Member
Has disclosed the following relevant financial relationships:
Consultant or advisor for: BeiGene; Janssen; Sanofi
Speaker or member of speakers bureau for: BeiGene; Janssen
Research funding from: BeiGene; Janssen
Steering Committee Member
Has disclosed the following relevant financial relationships:
Consultant or advisor for: AbbVie; AstraZeneca; BeiGene; Bristol Myers Squibb; Eli Lilly and Company; Janssen; Merck Sharp & Dohme
Speaker or member of speakers bureau for: AbbVie; AstraZeneca; BeiGene; Janssen; Merck Sharp & Dohme; Roche
Research funding from: AbbVie; AstraZeneca; BeiGene; Gilead; Janssen; Roche
Steering Committee Member
Has disclosed the following relevant financial relationships:
Consultant or advisor for: AstraZeneca
Speaker or member of speakers bureau for: AbbVie; BeiGene; Janssen
Research funding from: AbbVie; BeiGene; Janssen
Steering Committee Member
Has disclosed the following relevant financial relationships:
Consultant or advisor for: AbbVie; AstraZeneca; BeiGene; Janssen
Speaker or member of speakers bureau for: AbbVie; AstraZeneca; BeiGene; Janssen
Steering Committee Member
Has disclosed the following relevant financial relationships:
Consultant or advisor for: AbbVie, Inc.; BeiGene, Inc.; Janssen Pharmaceuticals; Pharmacyclics, Inc.
Research funding from: AbbVie, Inc.; BeiGene, Inc.; Janssen Pharmaceuticals; X4 Pharma
Steering Committee Member
Has disclosed the following relevant financial relationships:
Consultant or advisor for: AbbVie; Adaptive Biotechnologies; Aptitude Health; Ascentage Pharma; AstraZeneca; BeiGene; Bristol Myers Squibb; Celgene; Genentech; Janssen; Lilly; MEI Pharma; Merck; ONO Pharmaceuticals; Pharmacyclics; Research to Practice; Takeda; TG Therapeutics; Verastem
Research funding from: Ascentage Pharma; AstraZeneca; Genentech; MEI Pharma; Novartis; Pharmacyclics; Surface Oncology; TG Therapeutics; Verastem